Table 1 Demographic characteristics, comorbidities and NOAC profiles of AF patients in the study
Characteristics | Total Number (n = 299) |
|---|---|
Age (years) | 82.5 (± 7.4) |
< = 64 years | 3 (1.0) |
65-74 years | 36 (12.0) |
> = 75 years | 260 (87.0) |
Gender | |
Female | 200 (66.9) |
Male | 99 (33.1) |
Smoking status | |
Non-smoker | 246 (82.3) |
Ex-smoker | 44 (14.7) |
Smoker | 9 (3.0) |
Drinking status | |
Non-drinker | 292 (97.6) |
Ex-drinker | 2 (0.7) |
Drinker | 3 (1.0) |
Social-drinker | 2 (0.7) |
Comorbidities | |
Hypertension | 288 (96.3) |
Diabetes mellitus | 161 (53.8) |
Congestive heart failure | 52 (17.4) |
Ischaemic heart disease | 49 (16.4) |
Previous stroke/TIA | 150 (50.2) |
Previous intra-cranial haemorrhage | 3 (1.0) |
Renal function | |
eGFR ≥ 60 mL/min/1.73 m2 | 143 (47.8) |
eGFR 30–59 mL/min/1.73 m2 | 150 (50.2) |
eGFR < 29 mL/min/1.73 m2 | 6 (2.0) |
Scores | |
CHA2DS2-VASc score | 5.38 (± 0.95) |
0–1 | 0 |
2–4 | 29 (9.7) |
≥5 | 270 (90.3) |
HAS-BLED score | 1.70 (± 0.69) |
NOAC at baseline | 175 (58.5) |
Dabigatran | 90 (30.1) |
Apixaban | 52 (17.4) |
Rivaroxaban | 25 (8.4) |
Warfarin | 8 (2.7) |
non-NOAC at baseline | 124 (41.5) |
Aspirin | 115 (38.5) |
Clopidogrel | 3 (1.0) |
None | 6 (2.0) |